UMB Grants Pumas-AI Exclusive License for Lyv, a Cutting-Edge Clinical Decision Support System

Company spun out of University of Maryland School of Pharmacy aims to leverage its approach — combining modern artificial intelligence (AI) with traditional mechanistic models — to arm health care professionals with the best data to provide personalized treatment trajectories for patients

BALTIMORE, May 7, 2020 /PRNewswire/ — Pumas-AI, a University of Maryland, Baltimore (UMB) startup company, has been granted worldwide, exclusive rights to Lyv, a cutting-edge clinical decision support system designed to help health care professionals personalize treatment trajectories for patients in real-time.

The Lyv platform leverages clinical research and Electronic Health Record (EHR) data from millions of patients to derive algorithms that can personalize health care delivery. Lyv will have modules for anti-infectives, anti-epileptics, anti-coagulants, and anti-cancer that can be used in a hospital setting, and can also incorporate algorithms during new drug development. By personalizing treatment, Lyv can help improve therapeutic success rates and minimize dosing errors.

“This could be a game-changing new tool for health care providers with regards to informing real-time decisions about patient treatments,” said Phil Robilotto, DO, MBA, associate vice president of UMB’s Office of Technology Transfer and director of UM Ventures. “We are very excited about the cutting-edge research behind Lyv, developed by faculty at the University of Maryland School of Pharmacy, and look forward to seeing how Pumas-AI leverages this innovative software’s potential.”

Click here to read more via UM Ventures